Alkermes plc, of Dublin, reported second-quarter revenues of $279.9 million compared to $304.6 million for the same period in 2018.

In what it called one of the largest pharmaceutical settlements on behalf of end payers in an antitrust case in the last decade, law firm Hausfeld reported this week that it reached a $55 million settlement with Celgene Corp. in a long-running class action, In re Thalomid and Revlimid Antitrust Litigation. 

Snap Bio Inc., of San Diego, and Torrey Pines Investment (TPI) reported that their joint early drug discovery program within the framework of the i2020 Accelerator has resulted in achieving the projected milestone in developing several small-molecule lead candidates for treatment of hepatocellular carcinoma and hepatoblastoma. 

Benchling Inc., of San Francisco, said it closed a $34.5 million series C funding led by Menlo Ventures with new investors Lead Edge Capital and Y Combinator Continuity and returning investors Benchmark and Thrive Capital. 

Alexion Pharmaceuticals Inc., of Boston, reported second-quarter revenues of $1.2 billion, a 15% increase compared to $1 billion in the same period last year. 

The FDA's Arthritis Advisory Committee (AAC) Thursday will consider a supplemental new drug application for Boehringer Ingelheim GmbH's Ofev (nintedanib) capsules as a treatment for systemic sclerosis-associated interstitial lung disease (SSc-ILD). 

Pluristem Therapeutics Inc., of Haifa, Israel, declared a 1-for-10 reverse stock split, effective as of the market opening on Thursday.